Celularity

Celularity is a clinical and commercial-stage biotechnology company specializing in off-the-shelf placental-derived allogeneic cell therapies and advanced biomaterial products. The company develops mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells (including CAR-T cells) targeting age-related diseases and serious unmet medical needs.

Manufacturing & CDMO Capabilities

Celularity operates a purpose-built, fully integrated manufacturing facility spanning 150,000 sq. ft. with laboratory and advanced manufacturing space. The facility is staffed by over 100 highly specialized scientists, engineers, and technicians. Manufacturing infrastructure includes:

• Clinical Scale Production: 9 Grade C/ISO 7 GMP suites and 6 Grade D/ISO 8 GMP labs, all GMP-capable
• Integrated Operations: Fully integrated process from placental sourcing through proprietary cell harvesting, selection, master cell bank establishment, advanced cell manufacturing, and cryopreservation
• CDMO Services: Supports both internal programs and strategic contract development and manufacturing partnerships
• Scalable Biosourcing: In-house GMP manufacturing with proprietary processing methods and product-specific CMC development

Platform & Pipeline

The company leverages two decades of science built on placental biology. Current pipeline includes 15+ active and completed clinical trials across allogeneic placental-derived cells and biomaterial candidates. The proprietary IMPACT manufacturing process is designed to optimize speed and scalability while maintaining inventory-ready, on-demand product availability.